Molecular biology of bladder cancer: Prognostic, and clinical implications

Anirban P. Mirra, Henry Lin, Ram Datar, Richard J Cote

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The role of various molecular determinants involved in the genesis, progression, and outcome of bladder cancer has been the focus of investigations for the past 2 decades. Increasingly, the analysis of the interplay between these molecular factors is taking center stage. We review herein the studies examining the effects of deregulation of the various molecules implicated in the cell cycle, apoptosis, and angiogenesis pathways and analyze the central role of p53 in regulating these pathways. Technological advancements enable detection and quantification of gene transcripts and protein products, helping us move toward achieving the goal of establishing diagnostic, prognostic, and therapeutic marker panels. Recent studies have therefore focused on multiple-marker analyses to generate informative panels that can have greater clinical value for bladder cancer management. The use of molecular marker panels can provide a more objective alternative to clinical parameters for diagnosis and treatment decisions. Clinical trials aimed at treating urothelial carcinoma based on a patient's molecular profile can be predicted to empower clinicians to personalize patient management through increased therapeutic efficacy.

Original languageEnglish
Pages (from-to)67-77
Number of pages11
JournalClinical Genitourinary Cancer
Volume5
Issue number1
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Molecular Biology
Cell Cycle
Therapeutics
Clinical Trials
Apoptosis
Carcinoma
Proteins

Keywords

  • Angiogenesis
  • Apoptosis
  • Cell cycle
  • Expression profiling
  • Molecular pathways
  • Multiple-marker analysis
  • Prognostic markers
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Molecular biology of bladder cancer : Prognostic, and clinical implications. / Mirra, Anirban P.; Lin, Henry; Datar, Ram; Cote, Richard J.

In: Clinical Genitourinary Cancer, Vol. 5, No. 1, 01.06.2006, p. 67-77.

Research output: Contribution to journalArticle

Mirra, Anirban P. ; Lin, Henry ; Datar, Ram ; Cote, Richard J. / Molecular biology of bladder cancer : Prognostic, and clinical implications. In: Clinical Genitourinary Cancer. 2006 ; Vol. 5, No. 1. pp. 67-77.
@article{9db39e927daf49e9a72ab837101a66f7,
title = "Molecular biology of bladder cancer: Prognostic, and clinical implications",
abstract = "The role of various molecular determinants involved in the genesis, progression, and outcome of bladder cancer has been the focus of investigations for the past 2 decades. Increasingly, the analysis of the interplay between these molecular factors is taking center stage. We review herein the studies examining the effects of deregulation of the various molecules implicated in the cell cycle, apoptosis, and angiogenesis pathways and analyze the central role of p53 in regulating these pathways. Technological advancements enable detection and quantification of gene transcripts and protein products, helping us move toward achieving the goal of establishing diagnostic, prognostic, and therapeutic marker panels. Recent studies have therefore focused on multiple-marker analyses to generate informative panels that can have greater clinical value for bladder cancer management. The use of molecular marker panels can provide a more objective alternative to clinical parameters for diagnosis and treatment decisions. Clinical trials aimed at treating urothelial carcinoma based on a patient's molecular profile can be predicted to empower clinicians to personalize patient management through increased therapeutic efficacy.",
keywords = "Angiogenesis, Apoptosis, Cell cycle, Expression profiling, Molecular pathways, Multiple-marker analysis, Prognostic markers, Urothelial carcinoma",
author = "Mirra, {Anirban P.} and Henry Lin and Ram Datar and Cote, {Richard J}",
year = "2006",
month = "6",
day = "1",
doi = "10.3816/CGC.2006.n.020",
language = "English",
volume = "5",
pages = "67--77",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Molecular biology of bladder cancer

T2 - Prognostic, and clinical implications

AU - Mirra, Anirban P.

AU - Lin, Henry

AU - Datar, Ram

AU - Cote, Richard J

PY - 2006/6/1

Y1 - 2006/6/1

N2 - The role of various molecular determinants involved in the genesis, progression, and outcome of bladder cancer has been the focus of investigations for the past 2 decades. Increasingly, the analysis of the interplay between these molecular factors is taking center stage. We review herein the studies examining the effects of deregulation of the various molecules implicated in the cell cycle, apoptosis, and angiogenesis pathways and analyze the central role of p53 in regulating these pathways. Technological advancements enable detection and quantification of gene transcripts and protein products, helping us move toward achieving the goal of establishing diagnostic, prognostic, and therapeutic marker panels. Recent studies have therefore focused on multiple-marker analyses to generate informative panels that can have greater clinical value for bladder cancer management. The use of molecular marker panels can provide a more objective alternative to clinical parameters for diagnosis and treatment decisions. Clinical trials aimed at treating urothelial carcinoma based on a patient's molecular profile can be predicted to empower clinicians to personalize patient management through increased therapeutic efficacy.

AB - The role of various molecular determinants involved in the genesis, progression, and outcome of bladder cancer has been the focus of investigations for the past 2 decades. Increasingly, the analysis of the interplay between these molecular factors is taking center stage. We review herein the studies examining the effects of deregulation of the various molecules implicated in the cell cycle, apoptosis, and angiogenesis pathways and analyze the central role of p53 in regulating these pathways. Technological advancements enable detection and quantification of gene transcripts and protein products, helping us move toward achieving the goal of establishing diagnostic, prognostic, and therapeutic marker panels. Recent studies have therefore focused on multiple-marker analyses to generate informative panels that can have greater clinical value for bladder cancer management. The use of molecular marker panels can provide a more objective alternative to clinical parameters for diagnosis and treatment decisions. Clinical trials aimed at treating urothelial carcinoma based on a patient's molecular profile can be predicted to empower clinicians to personalize patient management through increased therapeutic efficacy.

KW - Angiogenesis

KW - Apoptosis

KW - Cell cycle

KW - Expression profiling

KW - Molecular pathways

KW - Multiple-marker analysis

KW - Prognostic markers

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33749053635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749053635&partnerID=8YFLogxK

U2 - 10.3816/CGC.2006.n.020

DO - 10.3816/CGC.2006.n.020

M3 - Article

C2 - 16859582

AN - SCOPUS:33749053635

VL - 5

SP - 67

EP - 77

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -